ChemoCentryx, Inc., announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will participate in two upcoming investor conferences.
SAN CARLOS, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will participate in two upcoming investor conferences:
- Stifel 2021 Virtual Healthcare Conference
Fireside Chat Wednesday, November 17 at 2:00 p.m. Eastern Time
- Piper Sandler 33rd Annual Virtual Healthcare Conference
On-demand presentation available beginning Monday, November 22 at 10:00 a.m. Eastern Time
A live audio webcast of the Stifel fireside chat, as well as the on-demand Piper Sandler presentation can be accessed through the Investors section of the Company’s website at www.ChemoCentryx.com. Replays of both the Stifel and Piper Sandler presentations will be available on the Company’s website for two weeks following the respective presentation dates.
About ChemoCentryx
ChemoCentryx is a biopharmaceutical company commercializing and developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. In the United States, ChemoCentryx markets TAVNEOS™ (avacopan), the first approved orally-administered inhibitor of the complement 5a receptor as an adjunctive treatment for adult patients with severe active ANCA-associated vasculitis. TAVNEOS is also in late-stage clinical development for the treatment of severe Hidradenitis Suppurativa and C3 glomerulopathy (C3G). Additionally, ChemoCentryx has early-stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer. For more information visit www.chemocentryx.com
Contacts:
Susan M. Kanaya
Executive Vice President,
Chief Financial and Administrative Officer
investor@chemocentryx.com
Media:
Stephanie Tomei
408.234.1279
media@chemocentryx.com
Investors:
Lee Roth, Burns McClellan
212.213.0006
lroth@burnsmc.com
